21February

Notice for the Annual General Meeting of Novo Nordisk A/S ... Read more

07February

Novo Nordisk invests DKK 800 million in upgrading and expanding production facil ... Read more

21February

Notice for the Annual General Meeting of Novo Nordisk A/S ... Read more

14February

Novo Nordisk A/S – Share repurchase programme ... Read more

14February

Trading in Novo Nordisk shares by board members, executives and associated perso ... Read more

11February

Trading in Novo Nordisk shares by board members, executives and associated perso ... Read more

Contact Media

If you have any queries please feel free to contact Media Relations at Novo Nordisk headquarters or one of our global offices.

Contact Media Relations
 
Press material is intended for media.

 

Novo Nordisk Media


Full-year results for 2019: operating profit increased by 11% in Danish kroner and by 6% at constant exchange rates
 

5 February - Novo Nordisk today published the full-year financial report for 2019. 

Lars Fruergaard Jørgensen, president and CEO: "We are very satisfied with the financial performance in 2019. The results reflect an accelerated sales growth in International Operations and a strong launch of Ozempic® in particular in North America Operations and Region Europe. The Rybelsus® launch in the USA is off to a good start, and we are pleased with the CV label indication for Ozempic® in the USA and the EU recommendation to approve Rybelsus®, all for the benefit of patients."

Read all about our financial performance, outlook, R&D, our strategic aspirations, sustainability in the report

Read Novo Nordisk's Annual Report 2019

 


Rybelsus® recommended for approval for the treatment of adults with type 2 diabetes by the European regulatory authorities

oral semaglutide

31 January - Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorisation for Rybelsus® (oral semaglutide) for the treatment of adults with insufficiently controlled type 2 diabetes to improve glycaemic control as an adjunct to diet and exercise

“We are very excited about the positive opinion for Rybelsus®, as it is the first and only GLP-1 in a tablet, and we believe it has the potential to set a new standard for the treatment of type 2 diabetes in the EU,” said Mads Krogsgaard Thomsen, executive vice president and chief science officer. “A high proportion of people with type 2 diabetes does not achieve target blood sugar levels, which underpins the need for new and more efficacious solutions to better manage their disease.”

Read the full announcement on the approval 

Read more announcements 

 


Novo Nordisk and UNICEF partner to help prevent childhood overweight and obesity

20 November - Novo Nordisk and UNICEF have announced a new partnership to help prevent childhood overweight and obesity worldwide with an initial focus on interventions in Latin America and the Caribbean.

Under this partnership, the United Nations children’s agency and the global healthcare company will combine efforts to enhance knowledge and awareness on how to prevent overweight and obesity and address their root causes. The partnership will initially cover a period of three years.

“There is no doubt that childhood overweight and obesity is a public health crisis that requires immediate attention. Childhood overweight and obesity is more than an individual choice, this is everybody’s business. Together with UNICEF, we hope to help millions of children lead healthy lives and at the same time ease the burden of obesity to society,” said Novo Nordisk President and CEO Lars Fruergaard Jørgensen.

Read the full press release on the partnership

Read UNICEF's release

 


Scaling up China’s fight against type 2 diabetes

China's fight against type 2 diabetes

China is facing a diabetes crisis, with more than one in 10 people living with the condition. The Chinese government, however, is fighting back with ambitious plans to deploy the latest technology to bring the epidemic under control, as Novo Nordisk CEO Lars Fruergaard Jørgensen saw for himself during a recent visit.

Read CEO Lars Fruergaard Jørgensen's account from his visit to China

 


The technology behind tablets
 

production Denmark

What if medicines injected by millions could be delivered in tablets? After almost 100 years of delivering injectable therapies, Novo Nordisk’s R&D team is finding answers to this enduring question. Chief Science Officer Mads Krogsgaard Thomsen is leading the way and he reflects on the magnitude of the scientific challenge and the progress made in his laboratories.

Read Mads' reflections

 


Novo Nordisk to achieve target of 100% renewable power in production and launches new ambition aiming for zero environmental impact 
 

Circular for zero

Novo Nordisk intends to achieve the target to use only renewable electricity in its global production facilities by 2020. The announcement on 30 April followed a new investment in a 672-acre solar panel installation, roughly the size of 500 football fields, in North Carolina, US, which will provide power to Novo Nordisk’s entire US operations from early 2020. Novo Nordisk is the first pharmaceutical company in RE100 to use only renewable electricity in production. RE100 is a collaborative, global initiative of businesses committed to using 100% renewable electricity.

Read more about Circular for Zero and download the full press release on the environmental ambitions 

 


Red Cross and Novo Nordisk partner to tackle chronic care in humanitarian crises
 

The International Committee of the Red Cross (ICRC), the Danish Red Cross (DRC) and Novo Nordisk have partnered to tackle the growing issue of chronic diseases that affect millions of people living in humanitarian crises around the world. Focus will be on ensuring efficient supply of low-cost human insulin in vials to Red Cross globally; support for ICRC’s and DRC’s health programmes; 2-3 projects to provide care to people with hypertension and diabetes in humanitarian crises to be conducted within three years.

Read CEO Lars Fruergaard's reflections and more about the partnership

 


Calendar

World Obesity Day
04MarchGlobal

Annual Report 2019


Financial results 2020

6 May - first quarter

6 August - first 6 months

30 October - first 9 months

 


When Pâris was diagnosed with type 1 diabetes at the age of two, his mother Wendy began filming. She didn’t stop for 16 years. 

Watch the documentary, 'Safely in the Rainbow', on YouTube



Novo Nordisk in brief